Skip to main content

Table 1 Patients characteristics and main study results according to the 2 study groups (unfavourable and favourable)

From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab

  Whole group Unfavourable Favourable p value
(n = 46) (n = 29) (n = 17)  
Age (range) 67 (36–81) 66 (36–79) 67 (38–81) ns
Sex     
Males 30 (65%) 21 (72%) 9 (53%) ns
Females 16 (35%) 8 (28%) 7 (47%) ns
ECOG PS     
0-1 29 (63%) 18 (62%) 11 (65%) ns
2-3 17 (47%) 11 (38%) 6 (35%) ns
Metastatic sites     
1 7 (15%) 5 (17%) 2 (12%) ns
≥ 2 39 (85%) 24 (83%) 15 (88%) ns
Previous lines of treatment     
1 10 (22%) 6 (21%) 4 (9%) ns
≥ 2 36 (78%) 23 (89%) 15 (88%) ns
Treatment     
FOLFIRI/Cet 9 (19%) 6 (21%) 3 (23%) ns
Irinotecan/Cet 37 (81%) 23 (79%) 14 (77%) ns
Response rate     
PR 13 (26%) 2 (7%) 11 (65%) 0.007
SD 6 (16%) 3 (10%) 3 (18%) 0.8
DCR (PR + SD) 19 (41%) 5 (17%) 14 (82%) 0.0001
PD 27 (59%) 24 (83%) 3 (18%) 0.0001
Survival     
PFS(months) 3.3 3 8 < 0.0001
OS (months) 11 6 15 < 0.0001
  1. ECOG PS = Eastern Cooperative Oncology Group Performance Status.
  2. FOLFIRI = Fluorouracil, leucovorin, Irinotecan.
  3. Cet = Cetuximab.
  4. PR = Partial Response.
  5. SD = Stable Disease.
  6. DCR = Disease Control Rate.
  7. PD = Progressive Disease.